277 related articles for article (PubMed ID: 14749122)
21. The role of adrenomedullin in angiogenesis.
Ribatti D; Nico B; Spinazzi R; Vacca A; Nussdorfer GG
Peptides; 2005 Sep; 26(9):1670-5. PubMed ID: 16112409
[TBL] [Abstract][Full Text] [Related]
22. The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action.
Zhou S; Ye W; Zhang M; Liang J
Crit Rev Eukaryot Gene Expr; 2012; 22(2):149-60. PubMed ID: 22856432
[TBL] [Abstract][Full Text] [Related]
23. Tumor suppression through angiogenesis inhibition.
Arsham AM; Simon MC
Methods Mol Biol; 2003; 223():249-70. PubMed ID: 12777736
[No Abstract] [Full Text] [Related]
24. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.
Dewangan J; Kaushik S; Rath SK; Balapure AK
Life Sci; 2018 Jan; 193():9-19. PubMed ID: 29196053
[TBL] [Abstract][Full Text] [Related]
25. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.
Allen E; Missiaen R; Bergers G
Cold Spring Harb Symp Quant Biol; 2016; 81():21-29. PubMed ID: 28396525
[TBL] [Abstract][Full Text] [Related]
26. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
27. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
28. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia: a key regulator of angiogenesis in cancer.
Liao D; Johnson RS
Cancer Metastasis Rev; 2007 Jun; 26(2):281-90. PubMed ID: 17603752
[TBL] [Abstract][Full Text] [Related]
30. Is HIF-1 alpha a valid therapeutic target?
Pili R; Donehower RC
J Natl Cancer Inst; 2003 Apr; 95(7):498-9. PubMed ID: 12671009
[No Abstract] [Full Text] [Related]
31. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
35. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
36. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
37. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
[TBL] [Abstract][Full Text] [Related]
38. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
39. New insights regarding vessel regression.
Im E; Kazlauskas A
Cell Cycle; 2006 Sep; 5(18):2057-9. PubMed ID: 16969103
[TBL] [Abstract][Full Text] [Related]
40. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
